- Home
- LGND vs VRDN Comparison
LGND vs VRDN Comparison
Compare LGND & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGND | VRDN |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.2B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | LGND | VRDN |
|---|---|---|
| Price | $184.16 | $27.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $243.50 | $41.42 |
| AVG Volume (30 Days) | 200.2K | ★ 1.4M |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.76 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $251,233,000.00 | $70,789,000.00 |
| Revenue This Year | $47.71 | $26,080.80 |
| Revenue Next Year | $9.77 | $2.07 |
| P/E Ratio | $73.82 | ★ N/A |
| Revenue Growth | 64.83 | ★ 23340.07 |
| 52 Week Low | $93.58 | $9.90 |
| 52 Week High | $212.49 | $34.29 |
Technical Indicators
Market Signals| Indicator | LGND | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 34.99 |
| Support Level | $179.20 | $28.44 |
| Resistance Level | $191.47 | $30.50 |
| Average True Range (ATR) | 7.53 | 1.47 |
| MACD | -1.51 | -0.41 |
| Stochastic Oscillator | 18.38 | 7.29 |
Price Performance
Historical ComparisonAbout LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).